TATDN1 Polyclonal antibody, PBS Only

• 

  WB analysis using 31840-1-AP (same clone as 31840-1-PBS)

  Various lysates were subjected to SDS PAGE followed by western blot with 31840-1-AP (TATDN1 antibody) at dilution of 1:2000 incubated at room temperature for 1.5 hours. This data was developed using the same antibody clone with 31840-1-PBS in a different storage buffer formulation.

• 

  IHC staining of mouse testis using 31840-1-AP (same clone as 31840-1-PBS)

  Immunohistochemical analysis of paraffin-embedded mouse testis tissue slide using 31840-1-AP (TATDN1 antibody) at dilution of 1:200 (under 40x lens). Heat mediated antigen retrieval with Tris-EDTA buffer (pH 9.0). This data was developed using the same antibody clone with 31840-1-PBS in a different storage buffer formulation.

TATDN1 Polyclonal Antibody for WB, IHC, Indirect ELISA

Cat No. 31840-1-PBS

Host / Isotype

Rabbit / IgG

Reactivity

human, mouse

Applications

WB, IHC, Indirect ELISA

Synonyms

CDA11, Deoxyribonuclease TATDN1, TatD DNase Domain Containing 1

---

Product Information

31840-1-PBS targets TATDN1 in WB, IHC, Indirect ELISA applications and shows reactivity with human, mouse samples.

• Tested Reactivity: human, mouse
• Host / Isotype: Rabbit / IgG
• Class: Polyclonal
• Type: Antibody
• Immunogen: TATDN1 fusion protein Ag36040
• Full Name: TatD DNase domain containing 1
• Observed Molecular Weight: 30 kDa
• GenBank Accession Number: BC064964
• Gene Symbol: TATDN1
• Gene ID (NCBI): 83940
• Conjugate: Unconjugated
• Form: Liquid
• Purification Method: Antigen affinity Purification
• UNIPROT ID: Q6P1N9
• Storage Buffer: PBS only, pH 7.3.
• Storage Conditions: Store at -80°C.

Background Information

Homo sapiens TatD DNase domain containing 1 (TATDN1), a member of the TATD family, is a highly conserved nuclease in both prokaryotes and eukaryotes with depurine/apyrimidine (AP) endonuclease activity, which plays an extremely important role in the genesis and prognosis of malignant tumors such as NSCLC and breast cancer, and is a potential therapeutic target for NSCLC patients who have failed to undergo cisplatin therapy (DDP) in vivo.